Giesen, N., Chatterjee, M., Scheid, C., Poos, A., Besemer, B., Miah, K., . . . Raab, M. (2023). A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma. Blood, 141(14), . https://doi.org/10.1182/blood.2022017789
Chicago Style (17th ed.) CitationGiesen, Nicola, et al. "A Phase 2 Clinical Trial of Combined BRAF/MEK Inhibition for BRAFV600E-mutated Multiple Myeloma." Blood 141, no. 14 (2023). https://doi.org/10.1182/blood.2022017789.
MLA (9th ed.) CitationGiesen, Nicola, et al. "A Phase 2 Clinical Trial of Combined BRAF/MEK Inhibition for BRAFV600E-mutated Multiple Myeloma." Blood, vol. 141, no. 14, 2023, https://doi.org/10.1182/blood.2022017789.
Warning: These citations may not always be 100% accurate.